The Raynaud
syndrome is a medical condition which is also known as Raynaud’s phenomenon.
A human body with this disease experience a pain in the extremities as this the
spasm of arteries causes episodes of reduced the flow of blood. Usually, the
fingers and less commonly the toes are included. Moreover, there are two main
types of this disease such as the primary Raynaud’s and the secondary
Raynaud’s. For instance, it is expected that this disease affects 5 to 10
percent of the Americans, but only 1 in 10 seek treatment. Whereas, the females
are an assessed nine times more likely to be affected than males. Hence, the
key players of this market are playing an important role by doing effective
advancement in the technology, development and innovations in the old
processing units and introduction of new healthcare institutions leads to the
effective growth during the forecasted period with the more proficiency in the
cure.
According to the report analysis, ‘Raynauds
Disease Global Clinical Trials Review, H1, 2018’ it is states that there are several key players
and health organizations which are recently functioning in this market more
effectively for dominating the handsome amount of market share by adopting the
effective techniques of doing treatment with the effective technology includes MediQuest
Therapeutics, Inc., Orion Corporation, Johnson & Johnson, Covis
Pharmaceuticals Inc, Apricus Biosciences Inc, Pfizer Inc, Otsuka Holdings Co
Ltd, Forenap Pharma E.U.R.L., Charles River Laboratories International Inc, Allergan
Plc, Fred Hutchinson Cancer Research Center, European Organization for Research
and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia
Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case
Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State
University, University of Pennsylvania, National Cancer Center, The University
of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial
Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group,
and several others. Not only has this, for the effective treatment of this more
and more innovated and developed laboratories are introduced with the more
developed instruments for doing test related to the cure of this disease.
On the basis
of geography, with the effective instrument of treatment and high prevalence of
the disease the market of this is spread around the globe more actively which
include Europe, Asia Pacific region, North America, Central and South America,
Middle East and Africa and Rest of the globe. In addition, both the forms of
this disease is frequent in the cold climate. When exposed to cold climate or
temperatures, the supply of blood to the toes or fingers, and in some cases the
noes or earlobes, is markedly decreased; the skin turns pale or white and
becomes cold and numb.
Although,
there is no proper treatment for this, but there are ways to maintain the symptoms.
For slight forms of this, wrapping the exposed the skin before leaving the
house can support and beneficial. If an attack happens, saturating the affected
parts in warm, not hot, water can improve symptoms and protect them from
worsening. Furthermore, it is expected that the market of Raynaud disease will
increase more effectively across the globe over the recent few years with the
effective investment by the new investors in the technology of treatment.
To know more, click on the link below:-
Related Report:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
